Occult Hepatitis B Infection in Kidney Transplant Patients
Occult hepatitis B infection (OBI) is still a topic of debate worldwide. It is defined as the presence of hepatitis B virus (HBV) DNA in serum and/or liver from HBsAg-negative subjects. OBI may lead to the development of cirrhosis and hepatocellular carcinoma. It continues to present several unique...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2022-12-01
|
| Series: | The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy |
| Subjects: | |
| Online Access: | https://www.ina-jghe.com/index.php/jghe/article/view/861 |
| _version_ | 1797810491110719488 |
|---|---|
| author | Ida Ayu Pradnya Paramita I Dewa Nyoman Wibawa |
| author_facet | Ida Ayu Pradnya Paramita I Dewa Nyoman Wibawa |
| author_sort | Ida Ayu Pradnya Paramita |
| collection | DOAJ |
| description | Occult hepatitis B infection (OBI) is still a topic of debate worldwide. It is defined as the presence of hepatitis B virus (HBV) DNA in serum and/or liver from HBsAg-negative subjects. OBI may lead to the development of cirrhosis and hepatocellular carcinoma. It continues to present several unique challenges in organ transplantation despite the availability of an effective vaccine to prevent HBV infection and the introduction of oral therapy to treat HBV infection. HBV reactivation following organ transplantation can occur even in recipients with absent hepatitis B surface antigen and remains an important cause of morbidity and mortality. Concerning OBI complications, the screening of HBV DNA by the highly sensitive molecular means should be implemented for both recipients of organ transplant and organ transplant donors especially in highly endemic areas of HBV. In the era of potent antivirals and with evolving knowledge, HBsAg (+) renal transplant candidates and recipients can be monitored and successfully treated. Kidney organs from HBsAg-negative and anti-HBc–positive donors should be considered for transplant candidates after weighing the risk-benefit ratio. All transplant candidates should receive HBV vaccination if they are not immune to facilitate receipt of an organ from a donor with anti-HBc seropositivity. |
| first_indexed | 2024-03-13T07:09:39Z |
| format | Article |
| id | doaj.art-708ffdd46e7a40d3919d72ebfb0f11e1 |
| institution | Directory Open Access Journal |
| issn | 1411-4801 2302-8181 |
| language | English |
| last_indexed | 2024-03-13T07:09:39Z |
| publishDate | 2022-12-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy |
| spelling | doaj.art-708ffdd46e7a40d3919d72ebfb0f11e12023-06-06T04:45:36ZengInterna PublishingThe Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy1411-48012302-81812022-12-0123322623310.24871/2332022227-234809Occult Hepatitis B Infection in Kidney Transplant PatientsIda Ayu Pradnya Paramita0I Dewa Nyoman Wibawa1Internal Medicine Specialist Education Study Program, Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, IndonesiaDepartment of Internal Medicine, Faculty of Medicine, Udayana University/Sanglah Hospital, Denpasar, Bali, IndonesiaOccult hepatitis B infection (OBI) is still a topic of debate worldwide. It is defined as the presence of hepatitis B virus (HBV) DNA in serum and/or liver from HBsAg-negative subjects. OBI may lead to the development of cirrhosis and hepatocellular carcinoma. It continues to present several unique challenges in organ transplantation despite the availability of an effective vaccine to prevent HBV infection and the introduction of oral therapy to treat HBV infection. HBV reactivation following organ transplantation can occur even in recipients with absent hepatitis B surface antigen and remains an important cause of morbidity and mortality. Concerning OBI complications, the screening of HBV DNA by the highly sensitive molecular means should be implemented for both recipients of organ transplant and organ transplant donors especially in highly endemic areas of HBV. In the era of potent antivirals and with evolving knowledge, HBsAg (+) renal transplant candidates and recipients can be monitored and successfully treated. Kidney organs from HBsAg-negative and anti-HBc–positive donors should be considered for transplant candidates after weighing the risk-benefit ratio. All transplant candidates should receive HBV vaccination if they are not immune to facilitate receipt of an organ from a donor with anti-HBc seropositivity.https://www.ina-jghe.com/index.php/jghe/article/view/861occult hepatitis b infectionkidney transplantationend-stage renal disease |
| spellingShingle | Ida Ayu Pradnya Paramita I Dewa Nyoman Wibawa Occult Hepatitis B Infection in Kidney Transplant Patients The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy occult hepatitis b infection kidney transplantation end-stage renal disease |
| title | Occult Hepatitis B Infection in Kidney Transplant Patients |
| title_full | Occult Hepatitis B Infection in Kidney Transplant Patients |
| title_fullStr | Occult Hepatitis B Infection in Kidney Transplant Patients |
| title_full_unstemmed | Occult Hepatitis B Infection in Kidney Transplant Patients |
| title_short | Occult Hepatitis B Infection in Kidney Transplant Patients |
| title_sort | occult hepatitis b infection in kidney transplant patients |
| topic | occult hepatitis b infection kidney transplantation end-stage renal disease |
| url | https://www.ina-jghe.com/index.php/jghe/article/view/861 |
| work_keys_str_mv | AT idaayupradnyaparamita occulthepatitisbinfectioninkidneytransplantpatients AT idewanyomanwibawa occulthepatitisbinfectioninkidneytransplantpatients |